Universal Cells creates Universal Donor Stem Cells by editing the genes required for immune recognition. By using our recombinant Adeno-Associated Virus (rAAV) technology, we design and manufacture stem cell-based products that can be used as off-the-shelf cell therapies.
Universal Donor Cells are pluripotent and can differentiate into various cell types that can be used to treat a vast number of diseases. Learn more about the Universal Cells’ pipeline and partnerships.
Acquisition enables Astellas to fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas Tokyo, February 13, 2018 - Astellas Pharma Inc. (TSE: 4503, [...]
Tokyo, October 19, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today announced that Astellas Institute for Regenerative Medicine (“AIRM”) and [...]
Universal Cells to utilise CGT Catapult’s induced Pluripotent Stem Cells to create universally accepted cells for research and commercial use London, UK, 5 October 2017 – The Cell and Gene Therapy Catapult (CGT Catapult) today [...]